Edition:
United States

Biomarin Pharmaceutical Inc (BMRN.OQ)

BMRN.OQ on NASDAQ Stock Exchange Global Select Market

93.84USD
22 Sep 2017
Change (% chg)

$0.42 (+0.45%)
Prev Close
$93.42
Open
$93.18
Day's High
$93.97
Day's Low
$92.68
Volume
34,042
Avg. Vol
456,420
52-wk High
$100.50
52-wk Low
$78.43

Chart for

About

BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products... (more)

Overall

Beta: 1.84
Market Cap(Mil.): $16,373.57
Shares Outstanding(Mil.): 175.27
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.66 16.34
EPS (TTM): -- -- --
ROI: -- 15.09 14.66
ROE: -- 16.32 14.00

BRIEF-FDA not planning to hold advisory committee meeting for Biomarin's Pegvaliase BLA

* FDA not currently planning to hold advisory committee meeting for Biomarin's Pegvaliase Biologics License Application (BLA)

Sep 14 2017

BRIEF-FDA accepts Biomarin's Pegvaliase Biologics License Application

* FDA accepts Biomarin's Pegvaliase Biologics License Application (bla) and grants priority review designation

Aug 29 2017

BRIEF-BioMarin announces offering of $450 mln of 0.599 pct senior convertible notes

* BioMarin announces offering of $450 million of 0.599% senior subordinated convertible notes due 2024

Aug 07 2017

BRIEF-Biomarin announces offering of $450 mln of senior subordinated convertible notes due 2024

* Biomarin announces offering of $450 million of senior subordinated convertible notes due 2024

Aug 07 2017

BRIEF-BioMarin announces plans to progress both the 6e13vg/kg and 4e13 vg/kg doses of BMN 270, its investigational gene therapy for Hemophilia A, into phase 3 studies

* BioMarin announces plans to progress both the 6e13vg/kg and 4e13 vg/kg doses of BMN 270, its investigational Gene Therapy For Hemophilia A, into phase 3 studies

Aug 02 2017

BRIEF-Sarepta and Biomarin report execution of global settlement

* Sarepta Therapeutics and Biomarin Pharmaceutical Inc. Announce execution of a global settlement and a license agreement resolving exon skipping patent litigation

Jul 18 2017

BRIEF-Biomarin Pharmaceutical says plans to initiate phase 3 registrational study in Q4 2017 for BMN 270

* Biomarin's Investigational Gene Therapy for Hemophilia A at 6e13 vg/kg dose maintains average factor VIII levels within normal range for over one year

Jul 11 2017

BRIEF-BioMarin submits pegvaliase Biologics License Application to the U.S. FDA for treatment of phenylketonuria

* BioMarin submits pegvaliase biologics license application (BLA) to the U.S. FDA for treatment of phenylketonuria (PKU)

Jun 30 2017

BRIEF-Biomarin Q1 GAAP loss per share $0.09

* Q1 earnings per share view $-0.29 -- Thomson Reuters I/B/E/S

May 04 2017

Biomarin sets high price for rare pediatric brain disease drug

Biomarin Pharmaceuticals Inc said the annual price for its drug, which won U.S. approval on Thursday, to treat a rare and fatal type of pediatric brain disease is expected to be $486,000 after mandatory government discounts and rebates.

Apr 27 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $131.81 +0.06
Pfizer Inc. (PFE.N) $35.91 -0.06
Novartis AG (NOVN.S) CHF83.55 +0.60
Merck & Co., Inc. (MRK.N) $65.38 -0.22
Roche Holding Ltd. (ROG.S) CHF248.60 -0.40
Roche Holding Ltd. (RO.S) CHF248.90 -0.10
Abbott Laboratories (ABT.N) $51.91 +0.48
Bayer AG (BAYGn.DE) €110.15 -0.25
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €84.54 +0.67

Earnings vs. Estimates